Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology
News Sep 15, 2008
Calando Pharmaceuticals has announced that pre-clinical development of a second siRNA oncology therapeutic, CALAA-02, is underway. The intracellular target for CALAA-02 is HIF-2alpha, or Hypoxia Inducible Factor-2 alpha.
HIF-2alpha is overexpressed in a number of solid tumors and is critical for many aspects of tumorigenesis, such as metastasis, angiogenesis, tumor cell proliferation, and tumor response to radiation. HIF-2alpha has been difficult to target using traditional drugs but is effectively targeted by the proprietary siRNA in CALAA-02.
"We are encouraged by the results obtained thus far with our proprietary anti-HIF-2alpha siRNA and are excited to pursue
pre-clinical development of CALAA-02," said Calando CSO for siRNA delivery, Jeremy Heidel, Ph.D. "We expect our experience with CALAA-01 will simplify and accelerate CALAA-02 development."
Calando's first siRNA therapeutic, CALAA-01, which targets the M2 subunit of ribonucleotide reductase, is currently in a Phase I clinical trial. Calando intends to move CALAA-02 into the clinic in 2009 to demonstrate the ability of the RONDEL™ delivery system to rapidly enable the pathway from target identification through pre-clinical development to clinical application of siRNA therapeutics.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018